Drugs / [18F]MNI-968
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03082768 | Mar 2017 → Mar 2018 | — | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03142724 | May 2017 → Mar 2018 | — | Molecular NeuroImaging | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MNI-968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03142724 ↗ |
| Known as | PF-06730110 | “The overall goal of this protocol is to evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.” NCT03082768 ↗1“Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects” NCT03142724 ↗ |